34 research outputs found
Optimizing the time of doxil injection to increase the drug retention in transplanted murine mammary tumors
Sex hormonal milieus during the female fertility cycle modulate the tumor vascular permeability of breast cancer. It has been proposed that the liposomal formulated doxorubicin (ie, Doxil), given at the menstrual/estrous stage with the predicted highest tumor vascular permeability, allows significantly increased drug retention in the breast tumor. In the current study, syngeneic murine 4T1 mammary tumors were established on the backs of female BALB/c mice and Doxil was administered at particular mouse estrous cycle stages. The results indicated that Doxil administration during certain times in the mouse estrous cycle was crucial for drug retention in 4T1 tumor tissues. Significantly higher drug concentrations were detected in the tumor tissues when Doxil was administered during the diestrus stage, as compared to when the drug injection was given at all other estrous stages. Our study also showed that the tumor-bearing mice exhibited nearly normal rhythmicity of the estrous cycle post drug injection, indicating the feasibility of continual injection of Doxil at the same estrous cycle stage. By using 4T1 cells cultured in vitro, we showed that progesterone (P4) significantly inhibited cell proliferation and the production of six tumor-derived cytokines, eg, sTNF-RI, CXCL-16, GM-CSF, MIP-1Ī±, MIP-1Ī³, and Flt3-L. Some of these factors have been shown to be vascular modulators in diverse tissues. In this report, we demonstrated that the concentration of P4 in the plasma and/or estrous cycle stage of 4T1 tumor-bearing mice can be used to select the best time for administrating the liposomal anticancer drugs
Mammaglobin as a potential molecular target for breast cancer drug delivery
<p>Abstract</p> <p>Background</p> <p>Mammaglobin (MAM) has been used as a specific molecular marker for breast cancer diagnosis. Recently, several groups of researchers proposed a number of therapeutic strategies targeting this molecule. Some of the strategies are based upon an essential but not demonstrated hypothesis ā mammaglobin is associated with the surface of breast cancer cells, which strongly disputes the therapeutic strategies.</p> <p>Results</p> <p>We conducted a computer-based predictive analysis and identified a small fragment at the N-end of MAM as a potential transmembrane domain. We provided several evidences to demonstrate the presence of the membrane-associated MAM. We isolated the membrane protein components from known MAM positive breast cancer cells (MDA-MB361 and MDA-MB415). We showed that about 22ā64% of MAM proteins, depending upon the types of the cancer cells, directly attached on the membrane of breast cancer cells, by Western blotting assays. To directly visualize the presence of the membrane-bound MAM protein, we incubated the MAM positive cancer cells with FITC labeled anti-MAM antibody, and observed clear fluorescent signals on the surface of the cells. In studying the MAM protein distribution in human breast cancer tissues, we first identified two immunostain patterns that are associated with the membrane-bound MAM: the membrane stain pattern and luminary surface stain pattern. To test whether the membrane-associated MAM can serve as a molecular target for drug delivery, we conjugated anti-MAM antibody to human low-density lipoprotein (LDL) and loaded doxorubicin (Dox) in the core of LDL. Specific binding and cytotoxicity of the MAM targeted and Dox loaded LDL was tested in the MAM positive breast cancer cells <it>in vitro</it>.</p> <p>Conclusion</p> <p>We first showed that some of MAM protein directly associated with the surface of breast cancer cells. The membrane-associated MAM protein may be utilized as a useful molecular marker for breast cancer targeted drug delivery.</p
Membrane Progesterone Receptor Alpha as a Potential Prognostic Biomarker for Breast Cancer Survival: A Retrospective Study
Classically, the actions of progesterone (P4) are attributed to the binding of nuclear progesterone receptor (PR) and subsequent activation of its downstream target genes. These mechanisms, however, are not applicable to PRā or basal phenotype breast cancer (BPBC) due to lack of PR in these cancers. Recently, the function of membrane progesterone receptor alpha (mPRĪ±) in human BPBC cell lines was studied in our lab. We proposed that the signaling cascades of P4āmPRĪ± pathway may play an essential role in controlling cell proliferation and epithelial mesenchymal transition (EMT) of breast cancer. Using human breast cancer tissue microarrays, we found in this study that the average intensity of mPRĪ± expression, but not percentage of breast cancer with high level of mPRĪ± expression (mPRĪ±-HiEx), was significantly lower in the TNM stage 4 patients compared to those with TNM 1ā3 patients; and both average intensities of mPRĪ± expression and mPRĪ±-HiEx rates were significantly higher in cancers negative for ER, as compared with those cancers with ER+. However, after adjusting for age at diagnosis and/or TNM stage, only average intensities of mPRĪ± expression were associated with ER status. In addition, we found that the rates of mPRĪ±-HiEx were significantly higher in cancers with epithelial growth factor receptorā1 (EGFR+) and high level of Ki67 expression, indicating positive correlation between mPRĪ± over expression and EGFR or Ki67. Further analysis indicated that both mPRĪ±-HiEx rate and average intensity of mPRĪ± expression were significantly higher in HER2+ subtype cancers (i.e. HER2+ERāPRā) as compared to ER+ subtype cancers. These data support our hypothesis that P4 modulates the activities of the PI3K and cell proliferation pathways through the caveolar membrane bound growth factor receptors such as mPRĪ± and growth factor receptors. Future large longitudinal studies with larger sample size and survival outcomes are necessary to confirm our findings
Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway
Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor Ī±-mediated mechanisms
Lung cancer is the leading cause of cancer morbidity and mortality in the world. The incidence of lung cancer, particularly lung adenocarcinoma, is increasing in women compared to men. The role of sex hormones in the development of lung cancer has attracted substantial interest, but remains largely unknown. In this study, we demonstrated that membrane progesterone receptor Ī± (mPRĪ±) was expressed in a lung adenocarcinoma cell line, A549, and was located on the cell membrane. In additional experiments, we found that mPRĪ± functioned as an essential mediator for progesterone (P4)-induced inhibitory effects on cell migration and invasion of A549 cells. Furthermore, PP1 (an Src pathway inhibitor), when co-incubated with P4, synchronously enhanced the inhibitory effects of P4 on cell migration and invasion. To explore the mechanisms of inhibition, we found that P4 and PP1 induced a cascade of molecular signaling events, such as dephosphorylation of focal adhesion kinase (FAK) and downregulation of matrix metalloproteinase 9 (MMP-9). Our study provides a mechanistic view on the effects of P4 through mPRĪ±āSrc/FAK relevant pathways in human lung adenocarcinoma cells and may aid in the development of novel therapeutic tools for the treatment of lung cancer
Plant Virus Incorporated Hydrogels as Scaffolds for Tissue Engineering Possess Low Immunogenicity \u3cem\u3ein Vivo\u3c/em\u3e
Recommended from our members
Progesterone/Org inhibits lung adenocarcinoma cell growth via membrane progesterone receptor alpha
Background
The aim of this study was to determine whether progesterone could inhibit the growth of lung adenocarcinoma cells via membrane progesterone receptor alpha (mPRĪ±) and elucidate its potential mechanism. The relationship between mPRĪ± expression and the survival prognosis of lung adenocarcinoma patients was studied.
Methods
A mPRĪ± knockdown lung adenocarcinoma cell line was constructed and treated with P4 and Org (a derivative of P4 and specific agonist of mPRĪ±). Cell proliferation was assessed using CCKā8 and plate colony formation assays. Protein expression was detected by western blotting. A nude mouse model of lung adenocarcinoma was established to assess the antitumor effect of P4/Org in vivo.
Results
We initially determined that mPRĪ± could promote the development of lung adenocarcinoma through the following lines of evidence. High expression of mPRĪ± both at the mRNA and protein level was significantly associated with the poor prognosis of lung adenocarcinoma patients. The downregulation of mPRĪ± inhibited the proliferation of lung adenocarcinoma cells. We further showed that mPRĪ± mediates the ability of P4 to inhibit the growth of lung adenocarcinoma cells through the following lines of evidence: P4/Org inhibited the proliferation of lung adenocarcinoma cells; mPRĪ± mediated the ability of P4/Org to inhibit lung adenocarcinoma cell proliferation; mPRĪ± mediated the ability of P4/Org to inhibit the PKA (cAMPādependent protein kinase)/CREB (cAMP responsive element binding protein) and PKA/Ī²ācatenin signaling pathways; and P4/Org inhibited the growth of a lung adenocarcinoma tumor model in vivo.
Conclusions
In summary, the results of our study show that progesterone can inhibit lung adenocarcinoma cell growth via mPRĪ±